The UK and US have agreed to a major trade agreement that will preserve zero tariffs on British pharmaceutical shipments going into the American market.
Key Provisions of the Accord
As part of the deal, the UK has committed to raise spending on pharmaceuticals through the public health system. This commitment ensures that tariffs on these key products will be held at nothing for a duration of three years.
This deal is in response to previous threats to dramatically increase import taxes on branded drug products, with increases mentioned as high as double the cost.
"This arrangement with the United Kingdom reinforces the international landscape for innovative medicines and introduces long-overdue equity to transatlantic pharmaceutical trade," a release said.
Commercial Importance
Pharmaceuticals represent one of the Britain's most significant exports to the US, which is clearly the primary buyer for large British pharmaceutical firms.
Export figures show that in the 12 months prior to the third quarter, the UK shipped medicines valued at billions to the US. This figure made up nearly one-fifth of total UK exports in that span.
"This agreement safeguards work, increases capital expenditure and sets the stage for the UK to emerge as a global hub for life sciences," the Business and Trade Secretary remarked.
Key NHS Changes
The pact involves several key changes from the British government:
- Revised Affordability Limit: The UK will increase the affordability limit at which it considers new treatments to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a aim to raise total health service expenditure on treatments from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The sum manufacturers must pay back to the NHS to stay within budget will be limited at fifteen percent. Last year, refunds were more than twenty percent.
Broader Context
The deal takes place against a long-running dispute between the pharmaceutical industry and the UK government over spending levels and NHS adoption.
This friction were intensified by claims that American customers were paying several times more for the identical medicines than people in the other developed nations.
Over the last 18 months, several large manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar funding commitments have been directed toward projects in the United States.
A senior figure stated that the NHS had to spend more on treatments, noting that its expenditure on drugs had declined as a percentage of its overall budget over the last ten years.
